Masimo CORP DEF 14A proxy statements

Masimo's Lead Independent Director addresses Politan Capital's concerns regarding potential vote manipulation in the upcoming Annual Meeting of Stockholders.

Masimo Corporation updated its website with information related to its 2024 Annual Meeting of Stockholders, addressing a potential separation of its consumer business and ongoing proxy solicitation.

Masimo Corporation issued a statement refuting claims made by Politan Capital in an effort to persuade shareholders to vote for Masimo's nominees, Joe Kiani and Christopher Chavez, at the upcoming annual meeting.

Masimo Corporation updated its website with materials related to its 2024 Annual Meeting of Stockholders, including letters of support and information regarding a conditional resignation, amidst an ongoing proxy solicitation.

Masimo urges stockholders to vote for its nominees, Joe Kiani and Christopher Chavez, highlighting Chavez's independence and medtech experience while criticizing Politan's nominees as potentially compromising the company's value.

Masimo is actively campaigning against Politan Capital's attempt to gain control of the company, arguing that Politan's actions threaten stockholder value and the company's innovation-driven growth strategy.

Politan Capital Management is soliciting proxies to elect two independent director candidates, William Jellison and Darlene Solomon, to Masimo Corporation's board at the 2024 annual meeting, aiming to improve corporate governance and shareholder value.

Masimo Corporation updated its website, www.ProtectMasimosFuture.com, on June 20, 2024, in connection with its upcoming 2024 Annual Meeting of Stockholders.

Masimo refutes claims made by Politan Capital in its proxy statement, alleging inaccurate and misleading information regarding the company's onboarding process, board processes, and handling of the consumer business separation.

Masimo launches a website to defend its strategy in connection with its 2024 Annual Meeting of Stockholders, highlighting its innovations, legal battles with Apple, and forward-looking statements regarding a potential separation of its consumer business.

Masimo's board is urging stockholders to vote for their nominees, Joe Kiani and Christopher Chavez, warning of potential value destruction if Politan Capital gains control.

Masimo is navigating a proxy contest while evaluating a potential separation of its consumer business to unlock stockholder value.

Masimo discusses its healthcare business performance, consumer business separation plans, and ongoing proxy fight with Politan Capital in a recent Goldman Sachs conference.

Masimo clarifies its position on settlement negotiations with Politan Capital Management, addressing concerns about board control and the nomination of Chris Chavez.

Masimo nominates medical device veteran Christopher Chavez to its Board of Directors and extends a third settlement offer to Politan Capital Management, which was subsequently rejected.

Masimo CEO Joe Kiani discusses the ongoing proxy fight with Politan Capital, the potential spinoff of the consumer business, and the launch of the Stork baby monitor in a recent interview.

Masimo's CEO, Joe Kiani, anticipates a favorable outcome in the upcoming shareholder vote, citing concerns over Politan Capital's attempt to gain control of the company and replace him.

Masimo responds to Politan Capital's demand for inspection of company books and records, raising concerns about unauthorized disclosure of information related to a potential joint venture.

Masimo publicly responds to Politan Capital's rejection of a board seat offer for their nominee, expressing disappointment and a desire to avoid a costly proxy fight.

Masimo Corporation is attempting to settle with Politan Capital Management to avoid a proxy contest by offering a board seat to one of Politan's nominees.

Masimo CEO Joe Kiani publicly refutes allegations from activist investment fund Politan Capital Management, led by Quentin Koffey and Michelle Brennan, regarding board representation and strategic decisions, including a potential spin-off of the consumer business.

Masimo defends against Politan Capital's attempt to gain control of the board, asserting that Politan's actions are not in the best interests of stockholders or patients.